RANGAP1: A drug target and biomarker for the treatment of cancer

Target Name: RANGAP1

NCBI ID: G5905

RANGAP1

RANGAP1: A drug target and biomarker for the treatment of cancer

Abstract:

RANGAP1, a gene encoding a protein involved in cell signaling pathways, has been identified as a potential drug target and biomarker for the treatment of cancer. The aim of this article is to review the current literature on RANGAP1, its functions, and its potential as a drug target and biomarker in cancer.

Introduction:

Cancer is a leading cause of death worldwide, with over 80% of deaths due to cancer. The development and progression of cancer are influenced by various genetic and epigenetic factors, including gene mutations, copy number variations, and expression levels of cancer-related genes . Therefore, identifying potential drug targets and biomarkers for cancer treatment is crucial for improving our understanding of the disease and developing new, more effective therapies.

RANGAP1: A protein involved in cell signaling pathways

RANGAP1, which stands for Rho-associated GTPase-activating protein 1, is a gene encoding a protein involved in cell signaling pathways. It is a 21 kDa protein that plays a critical role in regulating the actinin cytoskeleton and cell adhesion. RANGAP1 is a member of the Rho family of GTPases, which are involved in regulating protein interactions and cytoskeleton organization.

Functional characterization of RANGAP1

RANGAP1 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of actinin cytoskeleton dynamics and the organization of actinin-based signaling pathways. to be involved in cell survival and proliferation, as well as in the regulation of cell cycle progression.

In addition to its role in cell signaling pathways, RANGAP1 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. It has been shown to play a role in the regulation of actinin cytoskeleton dynamics and the organization of actinin-based signaling pathways. RANGAP1 has also been shown to be involved in cell survival and proliferation, as well as in the regulation of cell cycle progression.

Potential as a drug target

The potential of RANGAP1 as a drug target is due to its involvement in various cellular processes that are associated with cancer development. RANGAP1 has been shown to be involved in the regulation of actinin cytoskeleton dynamics, which are critical for cell adhesion and migration. Additionally, RANGAP1 has been shown to play a role in cell survival and proliferation, which are crucial processes for cancer development.

Furthermore, RANGAP1 has also been shown to be involved in the regulation of cell cycle progression, which is a critical process for cancer development. Therefore, RANGAP1 is an attractive target for cancer treatment, as inhibition of its function may lead to the inhibition of various cellular processes that are associated with cancer development.

Potential as a biomarker

RANGAP1 has also been shown to be a potential biomarker for cancer. The expression of RANGAP1 has been shown to be associated with various cancer types, including breast, lung, and ovarian cancer. Additionally, high expression of RANGAP1 has been shown to be associated with poor prognosis in cancer patients. Therefore, RANGAP1 may be a useful biomarker for the diagnosis and prognosis of cancer.

Conclusion:

In conclusion, RANGAP1 is a gene encoding a protein involved in cell signaling pathways that has been identified as a potential drug target and biomarker for the treatment of cancer. The regulation of actinin cytoskeleton dynamics, cell adhesion, migration, and invasion, as well as cell survival and proliferation, are processes that are associated with cancer development. Therefore, inhibition of

Protein Name: Ran GTPase Activating Protein 1

Functions: GTPase activator for RAN (PubMed:8146159, PubMed:8896452, PubMed:16428860). Converts cytoplasmic GTP-bound RAN to GDP-bound RAN, which is essential for RAN-mediated nuclear import and export (PubMed:8896452, PubMed:27160050). Mediates dissociation of cargo from nuclear export complexes containing XPO1, RAN and RANBP2 after nuclear export (PubMed:27160050)

The "RANGAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RANGAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets